Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Regenerative Medicine Company Vascudyne Relocates to High Capacity GMP Manufacturing Facility

Vascudyne, Inc.

Vascudyne, Inc., a biotechnology trailblazer in regenerative medicine, announced today that it has relocated to 15,000 sq. ft. of recently remodeled manufacturing, warehouse, laboratory, and office space. This new facility is needed to meet increased demand for research and development and manufacturing of Vascudyne’s TRUE™ Tissue technology that is unique and 100% natural. Nothing synthetic or artificial is ever used in the manufacturing process, in contrast to other regenerative medicine cardiovascular devices with synthetic polymer-based scaffolds that slowly degrade in the body and may lead to adverse immune response. Vascudyne announced in July the successful first human use of its TRUE™ Graft for hemodialysis access in end-stage renal disease patients. “The addition of a dedicated 5,000 sq. ft. ISO 7 Cleanroom manufacturing facility is paramount for the successful continuation of our TRUE Graft clinical studies,” said Cory Pries, Director of Quality at Vascudyne. “The expandable manufacturing capacity we have added is designed to support our current pilot clinical studies all the way to initial commercialization.” "We are dedicating 2,500 sq. ft. of the ISO 7 Cleanroom space to our new product development pipeline for coronary artery bypass graft, heart valves, and surgical patches," added Dr. Zeeshan Syedain, Vascudyne’s Chief Scientific Officer. “While we are initially focusing on cardiovascular applications for our TRUE Tissue technology, we can readily manufacture products and delivery systems for a range of medical devices, implantation sites, and geometries. We are excited to develop implantable biomaterials that are ready to use, off-the-shelf, and regenerative.” Vascudyne announced in December the closing of its Series A financing round for $10M that has fueled its growth and enabled the company’s relocation to the new facility. “Our investors’ continued support and promising early results from TRUE Graft’s first in man pilot study have propelled our growth,” said Rick Murphy, Vascudyne’s Chief Operating Officer. “We are establishing a strong presence in the epicenter of the Medical Alley, the Silicon Valley of Healthcare, and are creating excellent employment opportunities for talented people in the area. The move to this new facility positions us well to meet growing global demand for our products.” Vascudyne licensed its proprietary TRUE Tissue technology developed by world renowned tissue engineering leader Robert Tranquillo, PhD, Distinguished McKnight University Professor, and his colleagues from the University of Minnesota in 2017. TRUE Graft is not available for commercial sale. About Vascudyne Headquartered in the heart of Medical Alley in Minnesota, Vascudyne is on a mission to improve patient care with regenerative biomaterials that are inspired by nature. Vascudyne, a privately held company founded in 2014, uses the TRUE™ Tissue technology to develop TRUE to Nature™ biomaterials for soft tissue repair and replacement. For more information, please visit https://www.vascudyne.com/. About TRUE Tissue Technology TRUE™ Tissue is developed from cells isolated from donor tissue and is 100% biological. There are no synthetic materials or chemical fixation used, and implanted tissues are completely cell-derived and acellular. The TRUE Tissue technology can be readily shaped into tubes, sheets, and other geometries making it suitable for many soft tissue applications, is mechanically comparable to native tissues, and is a ready to use, off-the-shelf allograft. Forward Looking Statements This announcement contains forward-looking statements. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements relate to future events or Vascudyne’s clinical development programs, reflect management’s current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Vascudyne’s actual results, performance or achievements to be materially different. Vascudyne undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. Contact Details Sandy Williams, Marketing Director swilliams@vascudyne.com Company Website https://vascudyne.com/

February 09, 2022 09:23 AM Eastern Standard Time

Image

Shatterproof Receives $5 Million Gift from MacKenzie Scott

Shatterproof

Shatterproof, a national nonprofit organization dedicated to reversing the addiction crisis in the United States, today announced that it is a recipient of a $5 million grant from MacKenzie Scott, American philanthropist, to expand its work on addressing substance use disorder. The gift will be used to scale Shatterproof’s work using science-based solutions to make change by revolutionizing the addiction treatment system, breaking down addiction-related stigmas, educating and empowering our communities and addressing policy change at the federal and state level. Between April 2020 and May 2021, the CDC reported that United States experienced more than 100,000 overdose deaths which is a 30 percent increase from previous years. According to a study by SAMSHA on substance use and health, the COVID-19 pandemic has had a negative impact on the nation’s well-being and alcohol and drug use is impacting nearly 40 million Americans. “Our country is suffering, and it is critical that Shatterproof scale the implementation of its science-based strategies and get our tools and resources into the hands of as many of our loved-ones in need as possible,” shared Gary Mendell, Shatterproof Founder & CEO. “Thanks to the generosity of MacKenzie Scott, we will be able to continue to further grow our life-saving work. While we are proud of our results to date, there is so much more work to do to meet the needs of the millions of families impacted by this disease.” We are so grateful that she has recognized the importance of addressing this urgent need in our country and investing in Shatterproof.” In 2020, Shatterproof launched www.TreatmentATLAS.org, an Addiction Treatment Locator, Assessment and Standards (ATLAS®) platform, which aims to empower the public to find high-quality treatment services and ultimately drive the delivery of quality addiction treatment nationally. ATLAS is currently available in six states (DE, LA, MA, NY, NC, WV) and will expand to five more states this year (CA, FL, OK, NJ, PA). Shatterproof also launched the Movement to End Addiction Stigma, an evidence-based national strategy to address widespread stigma toward those with substance use disorder. Additionally, Shatterproof, in collaboration with The Hartford, released the Shatterproof Addiction Stigma Index a first-of-its-kind measurement tool, was designed to assess attitudes about substance use and people who use substances. Educational materials and helpful assessments and resources are available at www.Shatterprooff.org for individuals and families in need of help and support. About Shatterproof: Shatterproof is a national nonprofit organization dedicated to reversing the addiction crisis in the United States. Shatterproof harnesses the models of business, the rigor of science and the power of a national movement to create change and save lives through three pillars of work: revolutionizing the addiction treatment system, breaking down addiction-related stigmas and supporting and empowering our communities. To learn more visit www.Shatterproof.org. Contact Details Shatterproof Vanessa Shimer +1 203-954-8053 vshimer@shatterproof.org Company Website https://www.shatterproof.org/

February 08, 2022 03:02 PM Eastern Standard Time

GROUNDWORK BIOAG AND NOVATERO EXPAND MYCORRHIZAL BIO-PLATFORM FOR BRAZIL

Groundwork BioAg

Groundwork BioAg and its exclusive Brazilian distribution partner, NovaTero BioAg, announced a new product offering for Brazilian farmers this growing season – Rootella® BR ULTRA – which expands the reach to in-furrow and seed treatment application methods in soybean, corn and other cereals. Rootella BR ULTRA is the highest concentrated mycorrhizal inoculant in the market, containing 167,000 viable propagules per gram of Rhizophagus intraradices, with an application rate of as low as 15 grams per hectare. “As farmers manage the unseasonably dry weather, our expanded product portfolio offers additional choices for farmers in Brazil, especially as many switch to Safrinha,” said Bernardo Arnaud, NovaTero Chairman. “Farmers across Brazil continue to benefit from adding Rootella to their farm management practices to protect soil and plant health while extending above and below ground insurance against environmental stresses.” For the past three years, NovaTero has helped Brazilian farmers to naturally increase yield, reduce dependency on phosphorus and improve carbon sequestration in soil by applying the proven Rootella BR mycorrhizae inoculants. “As part of our strategy to expand our mycorrhizal bio-platform, we continue to set the standard for concentration of cost-effective, commercial scale mycorrhizae,” said Dr. Yossi Kofman, Co-Founder and CEO of Groundwork BioAg. “As the impact of climate change continues around the world, we are committed to help increase the productivity of major crops – like those in key breadbaskets such as Brazil. As the ‘queen of biologicals,’ mycorrhiza offers the strongest natural defense against chronic drought while reducing the need for synthetic fertilizers.” After being granted the only definitive commercial registration in Brazil, the companies’ exclusive partnership has accelerated innovation to meet demand of the rapidly growing Brazilian market, where the biologicals market is projected to show a double digit CAGR in the coming years. The Rootella BR portfolio includes two of the most concentrated formulations of mycorrhizae on the market today. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details AgTech PR for Groundwork BioAg Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

February 08, 2022 08:30 AM Central Standard Time

Kramer enriches its end-to-end solutions for Enterprise and Education applications with the new Kramer Collaboration Devices

Kramer Electronics

Kramer Electronics Ltd. is pleased to announce the release of its new Kramer Collaboration Devices, the latest addition to its end-to-end Pro AV solutions for Enterprise and Education applications. The new product line, which includes advanced cameras, a communication bar and a speakerphone, offers outstanding AV quality, flexibility and simplicity. Kramer’s complete solutions for Enterprise meeting spaces, schools and universities meet customers’ needs for complete, integrated solutions from a single, trusted partner that provides certified solutions, market-leading warranties and end-to-end support, all under one roof. Offering simple setup and seamless use, it is agnostic to all UC applications, and supports multiple conferencing platforms. Kramer Collaboration Devices are designed for varied spaces from small huddle rooms up to large boardrooms, classrooms and auditoriums. They ensure all participants, whether in the room or connecting remotely, consistently enjoy superb interactions, with an immersive audio and video experience. With Kramer Collaboration Devices, all participants can see and be seen as well as hear and be heard clearly – enabling meaningful and effective collaboration. An integral part of Kramer end-to-end solutions for Enterprise and Education applications, Kramer Collaboration Devices are fast and simple to deploy. They can easily be combined with Kramer's in-room A/V signal management and control products for a complete collaborative, hybrid experience. “With workplace norms and needs changing across business and education markets, our end-to-end solutions are building the foundation for truly inclusive hybrid interaction spaces,” says Gilad Yron, Kramer’s CEO. “The addition of the new line of Kramer Collaboration Devices is the latest step towards this vision, helping ensure engaging experiences for all participants and successfully bridging the gap between in-person and remote interactions.” The new Kramer Collaboration Devices product line includes: K-Speak – A compact speakerphone with 360° omnidirectional audio pickup that enhances the audio experience for everyone. Perfect for any room size where additional audio coverage is needed. K-Bar –An all-in-one video and audio communication bar that allows participants to quickly start collaborating. Ideal for small to mid-sized spaces where an all-in-one device saves space and cable clutter. K-180Mini – A smart, 4K wall-mount panoramic camera with integrated microphone, that captures clear video across a full 180° field of view. Designed for small rooms and huddle rooms. K-CamHD – A professional HD PTZ camera for versatile video capture that ensures a clear view of all meeting attendees, with special attention wherever needed. Ideal for varied spaces and use cases, ranging from medium sized rooms up to board rooms, classrooms and auditoriums. K-Cam4K –An ultra-HD PTZ camera for premium-clarity video in large spaces that puts every meeting in sharp focus, with crystal-clear, ultra-high-definition video capture. Supports the most advanced and challenging setups in large meeting rooms and educational spaces. About Kramer We are dedicated to delivering better, smarter solutions that enhance physical-digital engagement and collaboration. Kramer solutions are based on our cutting-edge products and technologies for traditional AV, AV over IP, unified communication and collaboration (UCC) and wireless collaboration, and advanced management and control. www.kramerav.com Contact Details Ornit Sade Benkin +972 52-332-7700 osade@kramerav.com Company Website https://www.kramerav.com/

February 08, 2022 08:00 AM Eastern Standard Time

AIHM Integrative Health & Medicine Fellowship Application Now Open

Academy of Integrative Health and Medicine

The Academy of Integrative Health and Medicine (AIHM) is now accepting applications for its Spring 2022 Fellowship cohort. Applications are available at https://aihm.org/fellowship/. AIHM’s Integrative Health and Medicine Fellowship is a hybrid program designed for busy health professionals who have completed postgraduate education and hold an active license in a healthcare profession. The 1,000-hour program, which blends online learning with a clinical immersion experience, provides clinicians the opportunity to explore the diverse applications of integrative medicine and learn effective, interprofessional tools that can immediately be incorporated into their practice and patient care model. “With patient interest in integrative therapies on the rise, and more clinicians embracing such practices, we expect more providers than ever to apply to our fellowship program this year,” said Dr. Erika Cappelluti, AIHM fellowship director. In addition to evidence-based online learning modules and a clinical immersion, clinicians attend three retreats during the fellowship, which cover topics such as nutrition, botanical medicine, dietary supplements, biofield science, Chinese medicine, yoga, and meditation—all explored in a dynamic, interpersonal, group setting. The AIHM Fellowship is approved by the American Board of Integrative Medicine (ABOIM) and recognized by the Academic Consortium for Integrative Medicine & Health. Graduating Fellows who hold an MD or DO degree may be eligible to sit for the board exam and become board certified through the ABOIM. All graduates will receive a certificate of completion and can use the FAIHM designation in their credentials. For more information, practitioners are encouraged to attend the virtual informational sessions: Open House with a Fellowship Graduate on Thursday, Feb. 10, at 5 p.m. PT Open House with Fellowship Faculty on Thursday, March 10, at 5 p.m. PT For additional information about the AIHM Fellowship Program, visit https://aihm.org/fellowship/. Founded in 1978, the Academy of Integrative Health and Medicine (AIHM) is the leading interprofessional organization for traditional, complementary and integrative health practitioners worldwide. In 2001, AIHM merged with the Academic Collaborative of Integrative Health (ACIH). Together, they are working to advance integrative health on a global scale and transform health and wellness through education, leadership, collaboration, research and advocacy. For more information, visit aihm.org or follow @aihmglobal on Facebook, Instagram, and Twitter. Contact Details Carol Stevenson +1 661-713-6879 carol@growthledge.com Company Website https://aihm.org

February 07, 2022 06:10 PM Eastern Standard Time

How The US is Leading the World to End COVID

YourUpdateTV

After two years of dealing with COVID issues, everyone is sick of arguing about masks and wants the supply chain fixed, the economy to rebound and kids to stay in school. The United States has been the global leader in the fight donating more than a half a billion vaccine doses and hundreds of millions of dollars. More needs to be done, and it’s in the hands of Congress to pass an emergency plan to End COVID Now. YourUpdateTV spoke to Michelle Nunn, President & CEO of CARE USA and Dr. Angela Wakhweya, CARE USA Senior Director, Health Equity and Rights Team to discuss how the US is leading the world to end COVID. A video accompanying this announcement is available at: https://youtu.be/vbbO4zX15Qw An emergency plan being considered by Congress will put billions of dollars into vaccines that could help reduce the risk of new variants developing that could threaten the United States and finally allow us to get back to normal. END COVID NOW is up with new advertisements across the country starting today, Lead The World and Variants are running nationwide on TV and cable as well as digital and streaming platforms. The Campaign to End COVID Now says This pandemic isn’t going away. Instead, it is a chronic disaster for everyone – families, communities, the whole country. The solution is straightforward and staring us in the face – we must achieve global immunity through ensuring everyone in the world has access to vaccines as quickly as possible. If not, we will continue to see variant after variant spread through our neighborhoods, disrupting and threatening our lives and our children’s lives. To learn more, visit EndCovidNow.com About the Campaign to End Covid: The End Covid Now campaign was formed by public health experts, scientists, and other concerned Americans to pressure our nation’s leaders and pharmaceutical companies to ensure future variants don’t shut down America. The plan to end COVID-19 consists of investing more money in vaccine manufacturing, sharing the vaccine formula so other countries can manufacture and distribute them, and working with allied countries to get more people vaccinated so Americans are safe from future variants. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 07, 2022 12:03 PM Eastern Standard Time

Video

The Greeley Company Names Sheri Winsper as VP of External Peer Review/Clinical Quality & High Reliability

Greeley

The Greeley Company (Greeley), a leader in clinical quality and patient safety, is pleased to announce that Sheri Winsper has joined the firm as Vice President of External Peer Review (EPR) and Clinical Quality & High Reliability (CQHR). Winsper brings deep expertise providing practical and sustainable solutions to enable organizations and the patients they serve to achieve high quality, safe, and efficient care. Through her EPR leadership, Winsper will collaborate with clients to provide practical, timely, and reliable performance measurement systems. Additionally, she will further advance Greeley’s CQHR consulting services through operational oversight, strategy development, and consultation. Winsper’s extensive healthcare experience includes a decade of acute care nursing and an additional 13 years of leadership in Clinical Quality & Patient Safety. She joins Greeley from National Quality Forum (NQF) where she served as Senior Vice President, Quality Measurement. In this role she worked strategically with NCQA, AHA, large health systems, CMS, AHRQ, the Veteran’s Administration, and America’s Health Insurance Plans (AHIP) to move quality measurement and improvement efforts toward making care high value for all. “My passion for data-driven, evidence-based programs that utilize nationally endorsed measures of risk reduction and high reliability outcomes closely aligns with Greeley’s commitment to helping organizations transform clinical practices,” Winsper said. “I’m thrilled to join a leading firm that provides best in class services, and I look forward to utilizing my EPR and CQHR experience to achieve the quality and highly reliable results organizations seek, and patients deserve.” Prior to her tenure at NQF, Winsper served as Vice President, Clinical Quality & Patient Safety/Chief Quality Officer at Texas Health Resources (THR). In this leadership capacity she provided system-wide leadership and risk management of clinical quality improvement, accreditation and regulatory operations, infection prevention, high reliability organization and culture of safety, and oversaw clinical risk management teams across multiple hospitals and physician clinics. Winsper served as Executive Director, Quality & Patient Safety, Center for Clinical Excellence (CCE) at Loyola University Health System prior to her position at THR. She also held several leadership positions at Baylor Scott & White Health (BSWH) including Vice President, COO/CQO of the STEEEP® Global Institute (SGI) and Vice President of Performance Measurement & Reporting at BSWH’s Institute for Health Care Research & Improvement. Winsper also previously served as Vice President, Clinical Quality, Health Research & Educational Trust (HRET) for American Hospital Association. Winsper received a Master of Science in Nursing Administration and a Master of Science in Health Care Administration from University of Texas at Arlington, TX. She received a Bachelor of Science in Nursing at Oklahoma Baptist University, Shawnee, OK. About The Greeley Company The Greeley Company (Greeley), a division of The Chartis Group®, is a leader in patient safety and clinical quality. Greeley has utilized its proven methodology to help organizations improve efficiency, comply with regulations and standards, achieve practitioner engagement and alignment, and excel in delivering high-quality, cost-effective patient care for more than 30 years. For more information, visit greeley.com. About The Chartis Group® The Chartis Group (Chartis) provides comprehensive advisory services and analytics to the healthcare industry. With an unparalleled depth of expertise in strategic planning, performance excellence, informatics and technology, digital and emerging technologies, and health analytics, Chartis helps leading academic medical centers, integrated delivery networks, children's hospitals and healthcare service organizations achieve transformative results. Chartis has offices in Atlanta, Boston, Chicago, New York, Minneapolis and San Francisco. For more information, visit chartis.com. Contact Details Hot Paper Lantern Brooke Ferreri +1 212-931-6182 bferreri@hotpaperlantern.com Company Website https://greeley.com/

February 07, 2022 09:00 AM Eastern Standard Time

G Medical Innovations (NASDAQ: GMVD) to Open One of the Largest COVID-19 Test Processing Labs and Walk-in Testing Facilities in the U.S.

G Medical Innovations Holdings

G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced that it has secured a 26,000 square foot site in Laguna, CA, to open one of the largest COVID-19 test processing laboratories in the United States for its G Medical Labs, Tests and Services division. “The new facility will enable us to process a dramatic increase in samples we have begun receiving via the distribution success of our LiveNow At-Home PCR test kits developed in partnership with McDade Products, LLC. The first million test kits began shipping to retailers nationally last week, and millions more will be on retailers’ shelves in the coming weeks,” said Dr. Yacov Geva, President, and CEO of G Medical Innovations. The Laguna lab will enable the company to process approximately 100,000 samples per day. The site will also offer same-day, walk-in COVID-19 PCR testing for the general public and has the capacity to process samples for other labs and entities that require expedited results. The facility is expected to open by next week. In January, Pittsburgh-based McDade Products, LLC and G Medical Tests and Services partnered to make millions of FDA EUA-approved COVID-19 PCR collection test kits available for retailers in response to a national shortage of COVID-19 test options. The LiveNow COVID-19 PCR Test Collection Kits provide 24 to 48-hour certified lab results and retail for $9.99. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. G Medical Labs, Tests and Services currently operates storefront testing locations in California. During the next few months, the company expects to expand its network of storefront testing locations in other U.S. regions to be announced at a later date. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial-stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. About McDade Group McDade Products is a division of McDade Group, a privately held specialty sales, marketing, and distribution company serving the U.S. retail industry. Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses opening one of the largest COVID-19 test processing laboratories in the United States, that the new facility will enable the company to process a dramatic increase in samples, distribution of At-Home PCR test kits, the processing capacity of the Laguna lab, and that it will offer same-day, walk-in COVID-19 PCR testing, the timing of the opening of the facility, and that during the next few months, the company expects to expand its network of storefront testing locations in other U.S. regions to be announced at a later date. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, the registration statement on Form F-1 filed on January 31, 2022 (registration no. 333-262422) and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Contact Details G-Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 Kobi@gmedinnovations.com Company Website https://gmedinnovations.com/

February 07, 2022 07:00 AM Eastern Standard Time

New Research Finds the Collaborative Care Model is Associated with Reductions in Racial Disparities in Mental Health Care for Pregnant People

Society for Maternal-Fetal Medicine

The collaborative care model, an evidence-based health intervention that is often used in primary care, has been shown to improve health outcomes for people with depression. It is a team-based approach where a physician collaborates with other professionals, including mental health practitioners, to proactively manage a patient’s mental health. The collaborative care model is not commonly used in obstetrics despite the fact that mental health conditions are one of the leading contributors to poor pregnancy outcomes. In a new study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™, which is being held virtually, researchers will unveil findings that suggest that implementing the collaborative care model during pregnancy not only is associated with improvements in the screening and treatment of depression in pregnancy, but is also associated with reductions in racial disparities in these important steps in mental health care. Researchers analyzed data from 4,710 pregnant and postpartum people who self-identified as either Black or White. Individuals were divided into two groups (before and after implementation of the collaborative care model) and results were analyzed by race. The primary goal of the research was to evaluate how often pregnant people were screened for depression. When a pregnant person screened positive for depression, the researchers also looked at how often treatment was recommended. In the first group, researchers examined data from August 2015 to September 2016 before the collaborative care model was implemented. In the second group, researchers looked at data from September 2017 to February 2019 after the collaborative care model was implemented. The study found that before the collaborative care model was implemented, there were significant disparities between Black and White pregnant people on screening for depression. After collaborative care was implemented, results showed the disparities between the two groups were eliminated. Similarly, for pregnant people who screened positive, implementation of the collaborative care model was associated with elimination of racial disparities in the recommendation for treatment. “In primary care, the collaborative care model allows mental health care to be seamlessly integrated into physical health care,” says one of the study’s authors Emily S. Miller, MD, MPH, a maternal-fetal medicine subspecialist and assistant professor at Northwestern University in Chicago. “In the field obstetrics, however, this model is not often utilized. What’s exciting about our research is that it demonstrates that we can implement a model — collaborative care — that has been used in primary care for years and apply it to the field of obstetrics to not only improve screening and treatment for depression, but also to promote equity.” The next step, say researchers, is to implement the collaborative care model in obstetrics care across the United States to help improve health outcomes for pregnant people with depression. The abstract has been published in the January 2022 supplement of the American Journal of Obstetrics and Gynecology (AJOG ) and can be accessed at no cost on the AJOG website. To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website or contact Karen Addis at karen@addispr.com or 301-787-2394. ### Contact Details Karen Addis +1 301-787-2394 KAREN@ADDISPR.COM Company Website https://www.smfm.org/

February 05, 2022 10:00 AM Eastern Standard Time

1 ... 239 240 241 242 243 ... 308